Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca drug ‘to become gold standard by 2012’

AstraZeneca drug ‘to become gold standard by 2012’

28th January 2009

AstraZeneca’s zibotentan will become Decision Resources’ proprietary clinical gold standard by 2012, it has emerged.

The product – which will hold the publication’s status through to 2017 – is used for the treatment of metastatic hormone-refractory prostate cancer.

It was chosen for its “overall efficacy, safety and tolerability and delivery measures”, which rival the current holder, Sanofi Aventis’ Taxotere therapy, the periodical noted.

The publication added the product has a “significant advantage”, in that it is likely to be administered orally.

Natalia Reoutova, analyst at Decision Resources, said key opinion leaders’ optimism, along with survey results, made zibotentan “the most likely agent” to become the gold standard treatment.

Last month, AstraZeneca and Pozen announced phase III study results, which compared PN 400 to enteric-coated naproxen 500 mg.

The study found patients taking the former had “significantly fewer” gastric ulcers than those taking the latter.

AsraZeneca noted two other studies – PN-400-307 and PN 400-309 – were still taking place.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.